DE602006015994D1 - Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer - Google Patents

Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer

Info

Publication number
DE602006015994D1
DE602006015994D1 DE602006015994T DE602006015994T DE602006015994D1 DE 602006015994 D1 DE602006015994 D1 DE 602006015994D1 DE 602006015994 T DE602006015994 T DE 602006015994T DE 602006015994 T DE602006015994 T DE 602006015994T DE 602006015994 D1 DE602006015994 D1 DE 602006015994D1
Authority
DE
Germany
Prior art keywords
combination
hemmer
imatinib
administration
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006015994T
Other languages
English (en)
Inventor
Sebastien Bihorel
Gerhard Gross
Michel Lemaire
Gian P Camenisch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0512843A external-priority patent/GB0512843D0/en
Priority claimed from GB0602264A external-priority patent/GB0602264D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602006015994D1 publication Critical patent/DE602006015994D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602006015994T 2005-06-23 2006-06-21 Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer Active DE602006015994D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0512843A GB0512843D0 (en) 2005-06-23 2005-06-23 Organic compounds
GB0602264A GB0602264D0 (en) 2006-02-03 2006-02-03 Organic compounds
PCT/EP2006/005960 WO2006136391A2 (en) 2005-06-23 2006-06-21 Treatment of solid tumor disease with combinations comprising imatinib and an efflux pump inhibitor

Publications (1)

Publication Number Publication Date
DE602006015994D1 true DE602006015994D1 (de) 2010-09-16

Family

ID=36763157

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006015994T Active DE602006015994D1 (de) 2005-06-23 2006-06-21 Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer

Country Status (6)

Country Link
US (1) US20080214445A1 (de)
EP (1) EP1951243B1 (de)
JP (1) JP2008546729A (de)
AT (1) ATE476183T1 (de)
DE (1) DE602006015994D1 (de)
WO (1) WO2006136391A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119077A1 (en) * 2007-03-28 2008-10-02 University Of Southern California Induction of differential stress resistance and uses thereof
WO2009083042A1 (en) * 2007-12-31 2009-07-09 Olaf Van Tellingen Methods and means for the treatment of cancer
WO2011018090A1 (en) 2009-08-11 2011-02-17 Andersen Stig Uggerhoej Predictive marker for hydroxyurea resistance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2748206B1 (fr) * 1996-05-06 1998-07-31 Solvay Pharma Utilisation de bromure de pinaverium dans la prevention des phenomenes proliferatifs des cellules du tractus hepatodigestif et des maladies qui en resultent
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
WO2004032925A1 (en) * 2002-10-11 2004-04-22 Novartis Ag Use of imatinib (glivec, sti-571) to inhibit breast cancer resistance protein (bcrp)-mediated resistance to therapeutic agents
GB0311971D0 (en) * 2003-05-23 2003-06-25 Novartis Ag Organic compounds
RU2007103703A (ru) * 2004-07-01 2008-08-10 Дзе Недзеландз Кэнсе Инститьют (Nl) Комбинация, включающая ингибитор бррм (белка резистентности рака молочной железы) и 4-(4-метилпиперазин-1-илметил)-n-(4-метил-3-(4-пиридин-3-ил)пиримидин-2-иламино)фенил)-бензамид

Also Published As

Publication number Publication date
JP2008546729A (ja) 2008-12-25
US20080214445A1 (en) 2008-09-04
ATE476183T1 (de) 2010-08-15
EP1951243A2 (de) 2008-08-06
WO2006136391A3 (en) 2007-03-15
WO2006136391A2 (en) 2006-12-28
EP1951243B1 (de) 2010-08-04

Similar Documents

Publication Publication Date Title
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
DE60219617D1 (de) Kombination von n- 5- 4-(4-methyl-piperazino-methyl)-benzoylamido -2-methylphenyl -4-(3-pyridil)-2pyrimidine-amin mit einem biphosphonat
CL2020003330A1 (es) Moléculas de ácido nucleico para la reducción de arnm de papd5 o papd7 para tratar la infección por hepatitis b (divisional solicitud no. 3561-2018)
RU2416611C2 (ru) Бициклические амиды как ингибиторы киназы
PE20220141A1 (es) Inhibidores de la proteina tirosina fosfatasa
PH12017500725A1 (en) Indole carboxamide compounds useful as kinase inhibitors
ATE499097T1 (de) Monozyklische heterozyklen als kinase-hemmer
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
EA201791946A1 (ru) Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
CY1105839T1 (el) 4-(4-μεθυλπιπepαζιν-1-υλμεθυλ)-ν-[4-μεθυλ-3-(4-πυριδιν-3-υλ)πυριμιδιν-2-υλ-αμινο)φαινυλ]-βενζαμιδη για τη θepαπεια αng ii - μεσολαβουμενων ασθενειων
ATE438401T1 (de) 1-aryl-4-substituierte piperazin-derivate zur verwendung als ccr1-antagonisten zur behandlung von entzündungen und immunerkrankungen
ATE447957T1 (de) Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen
PT1332137E (pt) Tratamento de tumores estromais gastrintestinais
ATE424208T1 (de) Proteinkinaseinhibitoren
ECSP066656A (es) COMBINACIÓN DE (a) N-{5-[4-(4-METIL-PIPERAZINO-METIL)-BENZOILAMIDO]2-METILFENIL}-4-(3-PIRIDIL)-2-PIRIMIDINA-AMINA Y (b) POR LO MENOS UN INHIBIDOR DE HIPUSINACIÓN Y EL USO DE LA MISMA
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
DE602006015994D1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ATE521354T1 (de) Kombination aus imatinib und einem histondeacetylase-hemmer zur behandlung von leukämie
RU2008127264A (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
EA201792148A1 (ru) Новые фармацевтические применения
DE102004015099A1 (de) Imidazolderivate
ATE386528T1 (de) Kombination von glivec (sti571) mit einem cyclinabhängigen kinaseinhibitoren, ins besonders flavopiridol, zur behandlung von krebs